Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

MLA

Weiss, Lena, et al. “Three-Month Life Expectancy as Inclusion Criterion for Clinical Trials in Advanced Pancreatic Cancer: Is It Really a Valid Tool for Patient Selection?” Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 26, no. 5, May 2024, pp. 1268–72. EBSCOhost, https://doi.org/10.1007/s12094-023-03323-1.

APA

Weiss, L., Heinemann, V., Fischer, L. E., Gieseler, F., Hoehler, T., Mayerle, J., Quietzsch, D., Reinacher-Schick, A., Schenk, M., Seipelt, G., Siveke, J. T., Stahl, M., Vehling-Kaiser, U., Waldschmidt, D. T., Dorman, K., Zhang, D., Westphalen, C. B., von Bergwelt-Baildon, M., Boeck, S., & Haas, M. (2024). Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 26(5), 1268–1272. https://doi.org/10.1007/s12094-023-03323-1

Chicago

Weiss, Lena, Volker Heinemann, Laura E Fischer, Frank Gieseler, Thomas Hoehler, Julia Mayerle, Detlef Quietzsch, et al. 2024. “Three-Month Life Expectancy as Inclusion Criterion for Clinical Trials in Advanced Pancreatic Cancer: Is It Really a Valid Tool for Patient Selection?” Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 26 (5): 1268–72. doi:10.1007/s12094-023-03323-1.